CRISPR Therapeutics AG 4

CFO Prasad Raju effected a non-open-market transfer (code G) of 750 CRISPR Therapeutics AG common shares, leaving him with 14,815 shares held directly.

On August 7, 2026, CRISPR Therapeutics AG Chief Financial Officer Prasad Raju reported a Form 4 transaction classified under code “G,” indicating a transfer of 750 common shares at a stated price of $0.00 per share, which is typically non-open-market and often reflects an internal transfer or gift rather than a discretionary purchase or sale. Following this transaction, Raju’s direct ownership stood at 14,815 common shares. With no market price data provided in the filing snapshot, the aggregate value of both the transferred shares and the remaining holdings must be treated as not determinable from the available information, but the zero-dollar notation and transfer code suggest an administrative or estate/plan-related movement rather than a value-driven trade.

Filing Facts

CIK

1674416

Ticker

CRSP

Form

4

Source Type

fda

Accession

0001193125-26-345111

Alert Tier

4